Adeno-associated virus (AAV) as a delivery vehicle. Production delays.

A recent article noted that recombinant AAV production facilities worldwide were currently committed to covid-19 vaccine production and that this might delay any proposed clinical trials to treat patients with Rett Syndrome. This short article provides some background on AAV and the difficulties in scaling up production to permit an expansion of clinical trials. Read more..

June 16, 2021
Return to All News Posts
Share this story
RETT Syndrome Association of Australia